Despite its prevalence, chronic idiopathic constipation (CIC) is often underdiagnosed, undertreated, and mismanaged, exacting a significant personal and economic burden for affected individuals. Overlapping symptoms with other functional gastrointestinal disorders complicate the diagnosis and treatment of CIC. There is a need for practical strategies in choosing and interpreting appropriate diagnostic tests, as well as a thorough understanding of safety and efficacy data in order to efficiently and effectively progress through the treatment continuum.
In this CME Outfitters OnDemand symposium, expert faculty will frame the CIC decision tree with patient cases in order to achieve a confident diagnosis, implement effective treatment plans to improve outcomes, and improve quality of life for patients with CIC.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in gastroenterology and/or primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Camilleri reports the following financial relationships: Consultant: Acadia Pharmaceuticals Inc.; Aditum Bio; AEON Biopharm; BioKier, Inc.; Colospan; Cosma Pharmaceuticals; Fauna Bio; Novome Biotechnologies, Inc.; Pfizer Inc.; Protagonist Therapeutics, Inc.; QED Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.; and Zealand Pharma A/S. Grants: NGM Biopharmaceuticals and Vanda Pharmaceuticals. Other financial or material support: option to receive stock for consulting with Bilayer Therapeutics; Dignify Therapeutics; Enterin Inc.; and Thelium Therapeutics
Dr. Cash reports the following financial relationships: Advisory Board: AbbVie Inc.; Phathom Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc. Consultant: Alexion; Motus; Nestle; and Phathom Pharmaceuticals. Research Support: Napo Pharmaceuticals, Inc. Speakers Bureau: AbbVie Inc.; Alnylam Pharmaceuticals, Inc; QOL Medical, LLC; RedHill Biopharma Ltd; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Harris reports the following financial relationships: Consultant: AbbVie (formerly Allergan); Alnylam Pharmaceuticals, Inc.; Gemelli Biotech; GI Health Foundation; Ironwood Pharmaceuticals, Inc.; Rome Foundation; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc. (formally Shire). Research Support: Allakos Inc.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.
Call us at 877.CME.PROS (877.263.7767).